Targeting vascular adhesion protein-1 to treat autoimmune and inflammatory diseases.
The development of new, safe, and effective anti-inflammatory drugs represents a major challenge for the pharmaceutical industry, as well as a significant opportunity. The increasing prevalence of chronic inflammatory and autoimmune diseases associated with an aging population has led to an intense effort to discover new anti-inflammatory drug targets and drugs acting against them. This review highlights the recent progress made in developing therapies directed against an endothelial cell adhesion molecule called vascular adhesion protein (VAP)-1 for the treatment of chronic inflammatory disease as well as highlighting other therapeutic opportunities offered by this vascular target.
Smith
David J
DJ
Biotie Therapies Corp., Tykistökatu 6, Turku, FIN-20520, Finland. david.smith@biotie.com
Vainio
Petri J
PJ
D006631:Amine Oxidase (Copper-Containing) / Q000378:metabolism*; D000818:Animals; D001327:Autoimmune Diseases / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D015815:Cell Adhesion Molecules / Q000378:metabolism*; D042783:Endothelial Cells / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000378:metabolism / Q000473:pathology
D015815:Cell Adhesion Molecules; D006631:Amine Oxidase (Copper-Containing)